搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
来自MSN
4 分钟
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial
by demonstrating “a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced ...
Health on MSN
4 小时
FDA Plans to Ban Ineffective Cold Medicine Ingredient—How It Will Affect You
The FDA had proposed removing phenylephrine, a widely used ingredient to treat nasal congestion, from over-the-counter cold ...
health enews
2 天
Nasal congestion on one side? You may have this condition
A deviated septum occurs when you have two different-sized nasal passageways which can cause one-sided congestion.
The Healthy on MSN
8 天
Chronic Nasal Congestion: 7 Reasons You Always Feel Stuffed Up
It’s this inflammation of the lining of your nose that produces the telltale stuffiness sensation of chronic nasal congestion ...
3 小时
on MSN
FDA proposes ending use of popular decongestant in cold medicines
The US Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups.
1 天
FDA proposes ending use of decongestant found in many cold, allergy medicines
An extensive review determined that the ingredient, oral phenylephrine, doesn’t actually relieve nasal congestion.
4 小时
Ineffective cough syrup ingredient should be axed officially, FDA says
A panel last year said it found evidence the ingredient, used in many popular medicines, did not aid with nasal congestion.
Detroit News
16 小时
Dr. Roach: Nasal decongestant causes a noticeable strain when urinating
I take 5 mg of Crestor and a multivitamin daily. I recently took a generic 12-hour, maximum-strength nasal decongestant to ...
1 天
U.S. FDA proposes ending use of popular decongestant present in cold medicines
The U.S. Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups, as an ...
FiercePharma
5 小时
AstraZeneca, Amgen's Tezspire scores in rhinosinusitis study
A phase 3 study has shown that when compared with placebo, Tezspire provided a statistically significant and clinically ...
14 小时
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH ...
Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈